StockData
Aquestive Therapeutics, Inc. logo

Aquestive Therapeutics, Inc. (AQST) stock

AQSTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 3/30
$3.70−0.06 (-1.60%)

Close on Nov 17, 2026Market cap $464.39MP/E –Yield –

Aquestive Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Aquestive Therapeutics's total assets was $132.10M at Jun 30, 2026. For fiscal 2025 it was $160.43M, up 58.2% from the year before. The highest annual figure on record is $160.43M in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$160.43M+58.2%
FY2024Dec 31, 2024$101.42M+76.6%
FY2023Dec 31, 2023$57.42M+0.6%
FY2022Dec 31, 2022$57.07M-7.9%
FY2021Dec 31, 2021$61.99M-1.4%
FY2020Dec 31, 2020$62.88M-19.9%
FY2019Dec 31, 2019$78.48M-9.6%
FY2018Dec 31, 2018$86.85M+101.4%
FY2017Dec 31, 2017$43.12M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$132.10M+41.0%
Q1 FY2026Mar 31, 2026$141.13M+38.0%
Q4 FY2025Dec 31, 2025$160.43M+58.2%
Q3 FY2025Sep 30, 2025$163.56M+48.7%
Q2 FY2025Jun 30, 2025$93.70M-20.3%
Q1 FY2025Mar 31, 2025$102.23M-21.1%
Q4 FY2024Dec 31, 2024$101.42M+76.6%
Q3 FY2024Sep 30, 2024$109.96M+85.0%
Q2 FY2024Jun 30, 2024$117.61M+106.3%
Q1 FY2024Mar 31, 2024$129.52M+111.3%
Q4 FY2023Dec 31, 2023$57.42M+0.6%
Q3 FY2023Sep 30, 2023$59.45M+14.7%
Q2 FY2023Jun 30, 2023$56.99M+1.2%
Q1 FY2023Mar 31, 2023$61.29M+8.4%
Q4 FY2022Dec 31, 2022$57.07M-7.9%
Q3 FY2022Sep 30, 2022$51.85M-20.6%
Q2 FY2022Jun 30, 2022$56.31M-15.8%
Q1 FY2022Mar 31, 2022$56.53M-8.7%
Q4 FY2021Dec 31, 2021$61.99M-1.4%
Q3 FY2021Sep 30, 2021$65.29M+29.5%
Q2 FY2021Jun 30, 2021$66.88M+5.2%
Q1 FY2021Mar 31, 2021$61.92M-4.0%
Q4 FY2020Dec 31, 2020$62.88M-19.9%
Q3 FY2020Sep 30, 2020$50.42M+3.3%
Q2 FY2020Jun 30, 2020$63.55M+26.1%
Q1 FY2020Mar 31, 2020$64.49M-5.1%
Q4 FY2019Dec 31, 2019$78.48M-9.6%
Q3 FY2019Sep 30, 2019$48.82M-45.8%
Q2 FY2019Jun 30, 2019$50.41M+16.9%
Q1 FY2019Mar 31, 2019$67.98M–
Q4 FY2018Dec 31, 2018$86.85M–
Q3 FY2018Sep 30, 2018$90.01M–
Q4 FY2017Dec 31, 2017$43.12M–

More Aquestive Therapeutics figures

See a number that looks wrong?